Last reviewed · How we verify
Iopamidol 370 mgI/mL
Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.
Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.
At a glance
| Generic name | Iopamidol 370 mgI/mL |
|---|---|
| Sponsor | Bracco Diagnostics, Inc |
| Drug class | Non-ionic iodinated contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iopamidol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It distributes throughout the vascular system and extracellular space, allowing visualization of blood vessels, organs, and anatomical structures during angiography, CT, and other imaging studies. The non-ionic formulation reduces osmolality compared to ionic contrast agents, lowering the risk of adverse reactions.
Approved indications
- Contrast enhancement for angiography and vascular imaging
- Contrast enhancement for computed tomography (CT) imaging
- Contrast enhancement for urography and other radiographic procedures
Common side effects
- Contrast-induced nephropathy
- Allergic reaction
- Nausea and vomiting
- Flushing and warmth sensation
- Headache
Key clinical trials
- Patients With Renal Impairment Undergoing CT (PHASE4)
- A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iopamidol 370 mgI/mL CI brief — competitive landscape report
- Iopamidol 370 mgI/mL updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI